Acne and oral contraceptives: Update on women's health screening guidelines

Journal of the American Academy of Dermatology

Volumn 58, Issue 5, 2008, Pages 781-786

  Frangos, Jason E ^a   Alavian, Christina N ^b   Kimball, Alexa B ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE; ACUTE HEART INFARCTION; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SCREENING; VENOUS THROMBOEMBOLISM;

ACNE VULGARIS; ADULT; CONTRACEPTIVES, ORAL; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; FEMALE; GENITALIA, FEMALE; HUMANS; PHYSICAL EXAMINATION; PRACTICE GUIDELINES AS TOPIC; VAGINAL SMEARS;

EID: 41949118812     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.12.040     Document Type: Article

References (50)

1. Strauss J.S., Krowchuk D.P., Leyden J.J., Lucky A.W., Shalita A.R., Siegfried E.C., et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 56 (2007) 651-663
2. Redmond G., Olson W., Lippman J., Kafrissen M., Jones T., and Jorizzo J. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89 (1997) 615-622
3. Lucky A., Henderson T., Olson W., Robisch D., Lebwohl M., and Swinyer L. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37 (1997) 746-754
4. Maloney M., Marbit D.I., Flack M., McLaughlin-Miley C., Sevilla C., and Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Health 2 (2001) 123
5. Bayer HealthCare Pharmaceuticals. Yaz package insert (2007) In press
6. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A., and Garner S.E. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 1 (2007) CD004425
7. American College of Obstetricians and Gynecologists. Oral contraceptives for adolescents: benefits and safety (1999), ACOG, Washington (DC)
8. Expert Working Group Meeting to Update the Selected Practice Recommendations for Contraceptive Use. Selected practice recommendations for contraceptive use. 2nd ed. (2004), World Health Organization, Geneva, Switzerland
9. Faculty of Family Planning and Reproductive Health Care, Royal College of Obstetricians and Gynaecologists. First prescription of combined oral contraceptions: recommendations for clinical practice. Br J Fam Plann 26 (2000) 27-38
10. Society of Obstetricians and Gynaecologists of Canada. Canadian Contraception Consensus. Clinical practice guidelines No. 143- part 2. Available at: http://sogc.medical.org/guidelines/public/143E-CPG2-March2004.pdf. Accessed October 2007.
11. IMAP statement on contraception for adolescents/young people in the era of HIV and AIDS. Available at: http://www.ippf.org/NR/rdonlyres/54B782C7-E761-4A76-8687-1A2B9D5C2CFB/0/IMAPstatementjune2006.pdf. Accessed October 2007.
12. World Health Organization and U.S. Agency for International Development. Recommendations for updating selected practices in contraceptive use, volume I (1994), World Health Organization and U.S. Agency for International Development, Washington (DC)
13. Harper C., Balistreri E., Boggess J., Leon K., and Darney P. Provision of hormonal contraceptives without a mandatory pelvic examination: the first stop demonstration project. Fam Plann Perspect 33 (2001) 13-18
14. Armstrong K.A., and Stover M.A. SMART START: an option for adolescents to delay the pelvic examination and blood work in family planning clinics. J Adolesc Health 15 (1994) 389-395
15. Stewart F.H., Harper C.C., Ellertson C.E., Grimes D.A., Sawaya G.F., and Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA 285 (2001) 2232-2239
16. Sawaya G.F., McConnell K.J., Kulasingam S.L., Lawson H.W., Kerlikowske K., Melnikow J., et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 349 (2003) 1501-1509
17. Screening for squamous cervical cancer-the duration of low risk following negative results in cervical cytology test: Introduction. IARC Working Group on Cervical Cancer Screening. IARC Sci Publ 76 (1986) 15-24
18. Padilla L.A., Radosevich D.M., and Milad M.P. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol 96 (2000) 593-598
19. U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med 2 (2004) 260-262
20. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion No. 357: Primary and preventive care: periodic assessments. Obstet Gynecol 108 (2006) 1615-1622
21. American College of Obstetricians and Gynecologists. ACOG practice bulletin. cervical cytology screening. No. 45. Int J Gynaecol Obstet 83 (2003) 237-247
22. US Preventive Services Task Force. USPSTF screening for cervical cancer. Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm. Accessed October 2007.
23. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. ACS guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
24. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
25. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
26. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
27. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (2007) 1-24
28. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Clinical Management Guidelines for Obstetrician-gynecologists. No. 61, April 2005. Human papillomavirus. Obstet Gynecol 105 (2005) 905-918
29. Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (2006) 1-94
30. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. 2005. Available at: http://www.ahrq.gov/clinic/uspstf05/gonorrhea/gonrs.htm. Accessed October 2007.
31. U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 147 (2007) 128-134
32. Petitti D.B. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
33. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107 (2006) 1453-1472
34. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. The use of hormonal contraception in women with coexisting medical conditions. Number 18. Int J Gynaecol Obstet 75 (2001) 93-106
35. World Health Organization. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. 3rd ed. (2003), World Health Organization, Geneva, Switzerland
36. Lewis M., Heinemann L.J., Spitzer W., MacRae K., and Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception 56 (1997) 129-140
37. Tanis B.C., van den Bosch M.A., Kemmeren J.M., Cats V.M., Helmerhorst F.M., Algra A., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
38. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349 (1997) 1202-1209
39. Kemmeren J.M., Tanis B.C., vandenBosch M.A.A.J., Bollen E.L.E.M., Helmerhorst F.M., vanderGraaf Y., et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 33 (2002) 1202-1208
40. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348 (1996) 498-505
41. Royar J., Becher H., and Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95 (2001) 370-374
42. Ness R.B., Grisso J.A., Klapper J., Schlesselman J.J., Silberzweig S., Vergona R., et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid Hormones and Reproductions. Am J Epidemiol 152 (2000) 233-241
43. Burkman R.T., Collins J.A., Shulman L.P., and Williams J.K. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185 2 Suppl (2001) S4-S12
44. Rivera R., Almonte H., Arreola M., Lopez F., Monarrez G., Navarro C., et al. The effects of three different regimens of oral contraceptives and three different intrauterine devices on the levels of hemoglobin, serum iron and iron binding capacity in anemic women. Contraception 27 (1983) 311-327
45. Davis A., Godwin A., Lippman J., Olson W., and Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 96 (2000) 913-920
46. Freeman E.W., Kroll R., Rapkin A., Pearlstein T., Brown C., Parsey K., et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10 (2001) 561-569
47. Vessey M., and Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 95 (2006) 385-389
48. Moreno V., Bosch F., Muñoz N., Meijer C., Shah K., Walboomers J., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-control Study. Lancet 359 (2002) 1085-1092
49. Smith J., Green J., de Gonzalez A., Appleby P., Peto J., Plummer M., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
50. Saraiya M., Ahmed F., Krishnan S., Richards T.B., Unger E.R., and Lawson H.W. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 109 (2007) 360-370